New code will improve the clarity of care, research, and insurance recognition for patients with Glanzmann thrombasthenia.
New York, October 1, 2026 /PRNewswire/ — The National Hemorrhagic Diseases Foundation ( NBDF ) announced that, in collaboration with the Glanzman Research Foundation and the CHES Foundation, its advocacy efforts have led to the establishment of a dedicated ICD-10-CM code for Glanzman thrombasthenia. Glanzman thrombasthenia is a rare hereditary platelet disorder. The new code, D69.11, will help clinicians, researchers, insurance companies, and public health systems more accurately identify this disease and better understand the needs of patients.
Granzmann thrombasthenia (GT) is a rare hereditary platelet dysfunction that affects the normal ability of blood to clot. (GT) Patients may experience frequent nosebleeds, easy bruising, gum bleeding, menorrhagia, and other serious bleeding complications.
Prior to this, although Glanzmann thrombasthenia has unique biological characteristics, symptoms, treatment considerations, and research needs, it was always classified under the same general code as other qualitative platelet disorders. Discussions with HEMAB Therapeutics and other stakeholders have highlighted the difficulties in identifying and tracking patients with Glanzmann thrombasthenia within existing medical data systems, as well as exposed the limitations of the current coding structure. Relevant discussions have also pointed out that there is increasing evidence suggesting that this disease may be underdiagnosed, and its prevalence may be higher than previously believed, which further emphasizes the need for more accurate identification and monitoring. Therefore, it has always been challenging to identify patients with Glanzmann thrombasthenia in claims data and medical records, as well as to accurately measure its prevalence, use of medical resources, treatment patterns, and overall disease burden.
At the same time, another new code D69.19 (other qualitative platelet defects) has also been introduced to cover diseases such as Bernard-Soulier syndrome and gray platelet syndrome.
For patients with Glanzmann thrombasthenia, the lack of a dedicated code makes it more difficult for the healthcare system to recognize the impacts of the disease, including recurrent and sometimes life-threatening bleeding, iron deficiency, anemia, missed school and work, as well as complex treatment requirements. ICD-10 is a standardized system used in the United States for diagnostic coding in medical records, insurance claims, public health reports, and research. A dedicated code will help with more accurate medical record keeping, more consistent billing and insurance coverage decisions, better identification of patients with Glanzmann thrombasthenia in research, and improved tracking of long-term outcomes. ICD-10-CM
NBDF submitted an application in 2024 to the National Center for Health Statistics ( NCHS ), which is under the United States Centers for Disease Control and Prevention ( CDC ). The application was reviewed in 2025 and was approved for implementation on October 1, 2026. NBDF stated that this effort reflects its commitment to advancing research, improving diagnostics, ensuring access to appropriate care, and ensuring that patients with rare hemorrhagic diseases are identified within the healthcare system. Healthcare providers and billing teams must update their electronic health record templates, billing systems, and charge lists in order to use the D69.11 code for patient visits on or after October 1, 2026.
NBDF, Senior Vice President of Research Strategy, Maria E. Santaella stated: "This achievement reflects something that NBDF is uniquely capable of doing: bringing together clinical and patient community experience, research evidence, and advocacy efforts to address the issues affecting patients with rare bleeding disorders. The exclusive code will help ensure that patients with Glanzmann thrombasthenia are no longer categorized within a broad group. They can now be counted, studied, and receive better services."
About the National Hemorrhagic Diseases Foundation of the United States ( NBDF )
The National Hemophiliia Foundation of America ( NBDF ) is committed to finding treatments for hereditary blood and bleeding disorders through research, education, and advocacy, as well as to addressing and preventing complications of these diseases, in order to help patients and their families live better lives. NBDF serves patients with various bleeding disorders across the United States, including those with hemophilia, von Willebrand disease, rare coagulation factor deficiencies, and platelet disorders. The organization was formerly known as the National Hemophiliia Foundation of America ( NHF ), and has since changed its name and domain name from hemophilia.org to bleeding.org.
